The Vitamin K2 space continues to grapple with significant Regulatory Challenges due to a lack of global harmonization regarding recommended daily intake (RDI). While many countries have established RDIs for Vitamin K1 (phylloquinone), no official RDI exists for K2 (menaquinones), despite robust evidence of its crucial extrahepatic roles. This inconsistency makes it difficult for brands to make standardized claims and navigate differing national standards.

In response, industry bodies are working to establish safety parameters grounded in clinical evidence. For instance, the Council for Responsible Nutrition (CRN) has established a Highest Observed Intake (HOI) of $375 \mu g$ per day for the highly bioavailable MK-7 form, based on studies showing no adverse effects on blood coagulation in healthy individuals. The primary hurdle now is developing a gold-standard biomarker—beyond current measures of uncarboxylated proteins—that accurately reflects the body's overall K2 status in extrahepatic tissues to justify universal dosage guidelines.

Related Reports